Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC-7366
- Development stage
- Phase 1
- Lead developer
- HiberCell
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HC-7366 is a first-in-class, orally bioavailable small molecule activator of the GCN2 (general control nonderepressible 2) kinase, also known as EIF2AK4. Developed by HiberCell, HC-7366 works by hyperactivating the GCN2 pathway, which triggers the integrated stress response (ISR) in tumor cells. This mechanism leads to the phosphorylation of eIF2α, resulting in the inhibition of general protein translation, cell cycle arrest, suppression of hypoxia-inducible factor (HIF), and the induction of apoptosis. HC-7366 is currently being evaluated in Phase 1 clinical trials for the treatment of various advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), and renal cell carcinoma (RCC), where it is being studied both as a monotherapy and in combination with agents such as the HIF-2α inhibitor belzutifan.
- Other names
- HC 7366HC7366HC-7366compound 29compound29compound-29
02
Targets
EIF2AK4 (Eukaryotic translation initiation factor 2-alpha kinase 4)
Beyond the preview
Go deeper on HC-7366.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC-7366.